
Trump to unveil new MAHA initiatives at 'Make Health Tech Great Again' White House event
The "Make Health Tech Great Again" event is expected to provide more details on how the administration is advancing a "next-generation digital health ecosystem," after securing partnerships with companies including Amazon, Anthropic, Apple, Google, and OpenAI to better share information between patient and providers within Medicare and Medicaid services.
"For decades, bureaucrats and entrenched interests buried health data and blocked patients from taking control of their health," Department of Health and Human Services Secretary Robert F. Kennedy, Jr. said in a statement Wednesday ahead of the event. "That ends today. We're tearing down digital walls, returning power to patients, and rebuilding a health system that serves the people. This is how we begin to Make America Healthy Again."
The Trump administration is partnering with more than 60 companies to bolster how health information is shared electronically, including through the use of apps, and beef up the interoperability of health information networks, according to the Centers for Medicare & Medicaid Services (CMS).
The apps aim to address issues including diabetes and obesity management, and provide beneficiaries with AI assistants to walk through symptoms, provide care options, and assist with scheduling appointments. Other functions that the technology aims to solve are providing digital check-ins to streamline services and cut down on paper intake forms.
The White House event is a follow-up to the request for information notice that the CMS posted in May requesting information from stakeholders on ways to beef up health technology interoperability.
Other technological advances on the health front include plans for CMS to launch an app library on Medicare.gov to best direct beneficiaries to the right digital health tools, according to CMS.
"We have the tools and information available now to empower patients to improve their outcomes and their healthcare experience," CMS Administrator Dr. Mehmet Oz said in a statement Wednesday.
"For too long, patients in this country have been burdened with a healthcare system that has not kept pace with the disruptive innovations that have transformed nearly every other sector of our economy," Oz said. "With the commitments made by these entrepreneurial companies today, we stand ready for a paradigm shift in the U.S. healthcare system for the benefit of patients and providers."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Broadcom launches Jericho chip to advance AI data center networks
By Max A. Cherney SAN FRANCISCO (Reuters) -Broadcom's silicon division launched its next-generation Jericho networking chip on Monday, which is designed to connect data centers over 60 miles (96.5 km) apart and speed artificial intelligence computation. The company's Jericho4 introduces and improves several features that increase the amount of networking traffic speeding across large networks that operate inside and between data centers. Building and deploying artificial intelligence has become more computationally intensive and requires stringing together thousands of graphics processors (GPUs). Cloud computing companies such as Microsoft and Amazon require faster, more sophisticated networking chips to ensure data moves efficiently. Security when transferring data beyond the physical walls of a data center is crucial for cloud companies because of the potential attacks that could intercept it ahead of reaching its destination. Broadcom's engineers designed the Jericho chips to be deployed at a massive scale, and a single system can encompass roughly 4,500 chips, according to Ram Velaga, senior vice president and general manager of Broadcom's Core Switching Group. To help mitigate issues around network congestion, the Jericho4 chips use the same high-bandwidth memory (HBM) designers such as Nvidia and AMD use for their AI processors. It's necessary because of the volume of data that needs to be stuffed into memory at any given moment of operation. "The switch is actually holding that traffic (in memory) till the congestion frees up," Velaga said. "It means you need to have a lot of memory on the chip." The longer the distance the data must travel from the chip to its destination, the more memory designers must include in the chip as well. In addition to performance improvements, the Jericho4 also beefs up security by encrypting data. Broadcom opted to use TSMC's three nanometer process for the Jericho4.
Yahoo
23 minutes ago
- Yahoo
Hims & Hers Health (NYSE:HIMS) Misses Q2 Revenue Estimates, Stock Drops 12%
Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market's revenue expectations in Q2 CY2025, but sales rose 72.6% year on year to $544.8 million. On the other hand, the company expects next quarter's revenue to be around $580 million, close to analysts' estimates. Its GAAP profit of $0.17 per share was 13% above analysts' consensus estimates. Is now the time to buy Hims & Hers Health? Find out in our full research report. Hims & Hers Health (HIMS) Q2 CY2025 Highlights: Revenue: $544.8 million vs analyst estimates of $550.8 million (72.6% year-on-year growth, 1.1% miss) EPS (GAAP): $0.17 vs analyst estimates of $0.15 (13% beat) Adjusted EBITDA: $82.24 million vs analyst estimates of $72.2 million (15.1% margin, 13.9% beat) The company reconfirmed its revenue guidance for the full year of $2.35 billion at the midpoint EBITDA guidance for the full year is $315 million at the midpoint, below analyst estimates of $319.4 million Operating Margin: 4.9%, up from 3.5% in the same quarter last year Free Cash Flow was -$69.43 million, down from $47.57 million in the same quarter last year Customers: 2.44 million, up from 2.37 million in the previous quarter Market Capitalization: $14 billion 'It's never been more clear that we are delivering exactly what millions of people have been waiting for: access to personalized, high-quality care that meets people where they are. From the momentum of our business to the results our customers are achieving, we are more confident than ever that our model is helping people optimize their health and realize the benefits of precision medicine,' said Andrew Dudum, co-founder and CEO. Company Overview Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE:HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Hims & Hers Health grew its sales at an incredible 78.1% compounded annual growth rate. Its growth surpassed the average healthcare company and shows its offerings resonate with customers, a great starting point for our analysis. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Hims & Hers Health's annualized revenue growth of 68.3% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. We can better understand the company's revenue dynamics by analyzing its number of customers, which reached 2.44 million in the latest quarter. Over the last two years, Hims & Hers Health's customer base averaged 43.3% year-on-year growth. Because this number is lower than its revenue growth, we can see the average customer spent more money each year on the company's products and services. This quarter, Hims & Hers Health achieved a magnificent 72.6% year-on-year revenue growth rate, but its $544.8 million of revenue fell short of Wall Street's lofty estimates. Company management is currently guiding for a 44.4% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 28.5% over the next 12 months, a deceleration versus the last two years. Still, this projection is healthy and indicates the market sees success for its products and services. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Although Hims & Hers Health was profitable this quarter from an operational perspective, it's generally struggled over a longer time period. Its expensive cost structure has contributed to an average operating margin of negative 1.7% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. On the plus side, Hims & Hers Health's operating margin rose by 43.9 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming in on its more recent performance, we can see the company's trajectory is intact as its margin has also increased by 13.6 percentage points on a two-year basis. These data points are very encouraging and show momentum is on its side. In Q2, Hims & Hers Health generated an operating margin profit margin of 4.9%, up 1.4 percentage points year on year. This increase was a welcome development and shows it was more efficient. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Hims & Hers Health's full-year EPS flipped from negative to positive over the last five years. This is a good sign and shows it's at an inflection point. In Q2, Hims & Hers Health reported EPS at $0.17, up from $0.06 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Hims & Hers Health's full-year EPS of $0.80 to grow 4.4%. Key Takeaways from Hims & Hers Health's Q2 Results We enjoyed seeing Hims & Hers Health beat analysts' EPS expectations this quarter. We were also happy its customer base narrowly outperformed Wall Street's estimates. On the other hand, its EBITDA guidance for next quarter missed and its revenue fell slightly short of Wall Street's estimates. Overall, this quarter could have been better. The stock traded down 12% to $55.84 immediately after reporting. Should you buy the stock or not? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Yahoo
23 minutes ago
- Yahoo
Tesla Awards Musk $29 Billion in Shares as 2018 Pay Battle Continues
Tesla (TSLA, Financials) granted CEO Elon Musk an interim award of 96 million shares, valued at about $29 billion, while his disputed $56 billion 2018 compensation package remains under review by the Delaware Supreme Court. The award will vest in two years if Musk stays as CEO or in another top role. It will be forfeited if the court clears the 2018 package, which was previously struck down by a Delaware judge as improperly approved. Shareholders re?approved that plan in June 2024. The move follows Tesla's weak quarterly results, with sales falling for a second straight quarter and automotive revenue down 16%. Musk warned of possible rough quarters ahead as EV tax credit cuts loom. The company will hold another shareholder meeting in November. This article first appeared on GuruFocus.